Enveric Biosciences (NASDAQ: ENVB) has announced positive findings from preclinical studies that support the metabolic profile of its leading candidate, EB-373. The absorption, distribution, metabolism, and excretion (ADME) as well as toxicology assays have demonstrated rapid conversion of EB-373 to the active metabolite psilocin. These results are consistent with previous animal pharmacokinetic (PK) studies.
In vitro assays using liver extracts derived from human, dog, rat, and mouse models have shown efficient conversion of EB-373 to psilocin across all species. These findings align with earlier animal studies that indicated a faster onset of acute peak neuroactive effects. Enveric plans to present comprehensive analyses of the preclinical ADME and toxicology studies for EB-373 at an upcoming scientific conference.
EB-373 is a novel chemical compound developed as a proprietary prodrug of psilocin for the next generation. It has displayed promising results in preclinical research for the treatment of anxiety disorders. Enveric believes that EB-373 has the potential to be well-tolerated with an improved